Business Description
Design Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US25056L1035
Total Employee Number:
54Description
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 81.5 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.04 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -4.5 | |||||
3-Year EPS without NRI Growth Rate | -2.3 | |||||
3-Year FCF Growth Rate | -0.5 | |||||
3-Year Book Growth Rate | -15.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -16.4 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 91.39 | |||||
9-Day RSI | 83.46 | |||||
14-Day RSI | 74.75 | |||||
3-1 Month Momentum % | -9.44 | |||||
6-1 Month Momentum % | 11.76 | |||||
12-1 Month Momentum % | 176.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 22.28 | |||||
Quick Ratio | 22.28 | |||||
Cash Ratio | 21.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.6 | |||||
Shareholder Yield % | -2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -32.54 | |||||
ROA % | -30.88 | |||||
ROIC % | -1149.31 | |||||
3-Year ROIIC % | 525.17 | |||||
ROC (Joel Greenblatt) % | -2616.62 | |||||
ROCE % | -36.55 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.48 | |||||
Price-to-Tangible-Book | 4.48 | |||||
EV-to-EBIT | -9.62 | |||||
EV-to-EBITDA | -9.69 | |||||
EV-to-FCF | -13.99 | |||||
| Price-to-Net-Current-Asset-Value | 4.55 | |||||
| Price-to-Net-Cash | 4.64 | |||||
Earnings Yield (Greenblatt) % | -10.4 | |||||
FCF Yield % | -5.54 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DSGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Design Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.2 | ||
| Beta | 1.369 | ||
| 3-Year Sharpe Ratio | 0.76 | ||
| 3-Year Sortino Ratio | 1.27 | ||
| Volatility % | 75.5 | ||
| 14-Day RSI | 74.75 | ||
| 14-Day ATR ($) | 0.971796 | ||
| 20-Day SMA ($) | 12.3915 | ||
| 12-1 Month Momentum % | 176.36 | ||
| 52-Week Range ($) | 3.52 - 17.25 | ||
| Shares Outstanding (Mil) | 62.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Design Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Design Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 122 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 32 days | ||
| General meeting for 2026 | 2026-06-09 08:00 | 10.46 (-2.79%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 13:25 | 10.44 (+2.86%) | ||
| 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich\'s ataxia | 2026-05-18 08:00 | 14.36 (+0.35%) | ||
| First quarter earnings results for 2026 | 2026-04-28 | 12.81 (+2.64%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-10 14:20 | 10.37 (+4.43%) | ||
| Annual report for 2025 | 2026-03-09 | 10.05 (+1.93%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-09 | 10.05 (+1.93%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-25 13:20 | 10.60 (+2.12%) |
Show
Entries
Design Therapeutics Inc Frequently Asked Questions
What is Design Therapeutics Inc(DSGN)'s stock price today?
The current price of DSGN is $15.65. The 52 week high of DSGN is $17.25 and 52 week low is $3.52.
When is next earnings date of Design Therapeutics Inc(DSGN)?
The next earnings date of Design Therapeutics Inc(DSGN) is 2026-08-07 Est..
Does Design Therapeutics Inc(DSGN) pay dividends? If so, how much?
Design Therapeutics Inc(DSGN) does not pay dividend.
Guru Commentaries on NAS:DSGN
No articles.
Press Release
Articles on Design Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers